{"id":"W4220847549","doi":"10.1136/jitc-2021-004233","title":"Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Canadian Institutes of Health Research; Pharmacyclics; Genentech; PharmaMar; Eisai; Syndax Pharmaceuticals; Clovis Oncology; BeiGene; Conquer Cancer Foundation; Merck KGaA; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Princess Margaret Cancer Foundation; Pfizer; Mersana Therapeutics","keywords":"Medicine; Nivolumab; Internal medicine; Oncology; Immunotherapy; Cabozantinib; Clinical endpoint; Endometrial cancer; Response Evaluation Criteria in Solid Tumors; Progression-free survival; Cancer; Clinical trial; Gastroenterology; Phases of clinical research; Chemotherapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001293944,0.000192319,0.001367334,0.0008530146,0.0001199999,0.000007872304,0.0001309243,0.00003715753,0.001968271],"category_scores_gemma":[0.0001842365,0.0001313594,0.0003769098,0.001294324,0.00009187385,0.0001515897,0.0000117089,0.0003321974,6.221952e-8],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003564433,"about_ca_system_score_gemma":0.0009325187,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006438865,"about_ca_topic_score_gemma":0.0004186047,"domain_scores_codex":[0.9972825,0.0002725717,0.001234609,0.0001989508,0.0007622365,0.0002491063],"domain_scores_gemma":[0.9979934,0.0007331028,0.0008760064,0.0001168315,0.0002236917,0.00005699487],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8143653,0.003843774,0.0003643979,0.00007839443,0.000693027,0.000008133894,0.0006595601,0.00060121,0.001725785,0.00006509598,0.00002499822,0.1775704],"study_design_scores_gemma":[0.9704422,0.02040775,0.0002510584,0.0002802727,0.0003010086,0.00001828552,0.0001611845,0.000223414,0.00209762,0.0004989465,0.005181697,0.0001365926],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9754911,0.01737028,0.0003773099,0.0009599251,0.001465454,0.003958285,0.000305487,0.000006195437,0.00006594722],"genre_scores_gemma":[0.9888441,0.007205149,0.001178052,0.0001001647,0.0001670689,0.001975887,0.00004181888,0.00003717993,0.0004506044],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1774338,"threshold_uncertainty_score":0.998944,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04021511302289515,"score_gpt":0.3943897692277361,"score_spread":0.354174656204841,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}